drugset / Trial / NCT00870454

An Efficacy and Safety Study of Carisbamate in the Treatment of Nerve Pain in Diabetics

NCT00870454

Phase 2 Completed 386 enrolled SK Life Science, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of carisbamate (800 and 1200 mg/day) in patients with diabetic neuropathic pain.

Timeline

Start
2009-05
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule 800 mg Oral
Subject Carisbamate Small molecule 1200 mg Oral
Comparator Pregabalin Small molecule 300 mg Oral